AstraZeneca: Pipeline, Products, Performance, Potential

Summary

Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Contents

• Executive Summary
  • introduction
  • Current Financial position
    • Company Performance
    • Business Segment Performance
    • Geographic Performance
  • Company Strategy
    • Key Agreements
  • product performance Forecasts
    • Discontinued Products
  • pipeline analysis
    • Discontinued R&D Projects
  • Conclusions
• Therapeutic Area Focus
• R&d Pipeline
• Cardiovascular
  • marketed products
    • Amlodin
    • Ephedrine Nagai
    • ProRenal
    • Others
  • R&D projects
    • Irbesartan
• Growth Forecast
• Oncology/Infection
  • marketed products
    • AmBisome
    • Meropen/Merrem
    • Others
  • R&D projects
    • Miriplatin hydrase
  • Growth Forecast
• Gastrointestinal
  • marketed products
    • Gasmotin
    • Others
  • R&D projects
  • Growth Forecast
• Inflammation/Allergy
  • marketed products
    • Ebastel
    • QVAR
  • R&D projects
    • SMP-028
    • SMP-114
  • Growth Forecast
• Central Nervous System
  • marketed products
    • Excegran/Exogran/Zonegran/Tremode
    • Others
  • R&D projects
    • AC-3933
    • Lonasen
    • Lurasidone
    • Ranirestat
  • Growth Forecast
• Diabetes
  • marketed products
    • Seibule
    • Others
  • R&D projects
    • Repaglinide
    • SMP-862
  • Growth Forecast
• Other
  • marketed products
    • Growject
• R&d Projects
  • • SMP-986
• Appendix 1 - Financial Performance
  • Full Year results 2007
• Appendix 2 - Key Corporate Events
• Appendix 3 - Key Agreements
  • Almirall Prodesfarma SA
  • Astellas Pharma
  • AstraZeneca
  • Bristol-Myers Squibb
  • Chelsea Therapeutics International Ltd
  • Conforma Therapeutics Corporation
  • Daewoong Pharmaceuticals
  • Eisai
  • Gilead Sciences
  • Idenix Pharmaceuticals Inc
  • Kissei Pharmaceutical Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Merck KGaA
  • Mitsubishi Pharma Corporation
  • Neurocrine Biosciences Inc
  • Novo Nordisk
  • Ono Pharmaceutical
  • Pfizer
  • Protez Pharmaceuticals Inc
  • Recordati
  • sanofi-aventis
  • Schering-Plough
  • Servier
  • Sunesis Pharmaceuticals Inc
  • Torii Pharmaceutical
  • Dainippon Sumitomo Pharma
• Appendix 4 - Infrastructure
  • research and Development Facilities
  • manufacturing Facilities
• Appendix 5 - Key Pharmaceutical
• Subsidiaries/Joint Ventures
  • Subsidiaries
  • Joint Ventures
• Index
• Index of Tables
  • Principal Operating Results
  • Capital Expenditure by Business Area
  • Sales by Business Area
  • Operating Income by Business Area
  • Identifiable Assets by Business Area
  • Major Products, Therapeutic Areas and Sales
  • Major Cardiovascular Products, 2007
  • Major Oncology/Infection Products, 2007
  • Major Gastrointestinal Products, 2007
  • Major Inflammation/Allergy Product, 2007
  • Major Central Nervous System Products, 2007
  • Major Diabetes Products, 2007
  • Other Products, 2007
• Index of Charts
  • Capital Expenditure by Business Area
  • Sales by Business Area
  • Operating Income by Business Area
  • Sales of Top Ten Products (2002A-2012E)
  • Top Ten Selling Products, 2007
  • Domestic R&D Pipeline
  • Overseas R&D Pipeline
  • Amlodin Sales (2002A-2012E)
  • ProRenal Sales (2002A-2012E)
  • Irbesartan Sales (2009E-2015E)
  • Meropen Sales (2002A-2012E)
  • Gasmotin Sales (2002A-2012E)
  • Ebastel Sales (2002A-2012E)
  • QVAR Sales (2002A-2012E)
  • Excegran Sales (2002A-2012E)
  • Lonasen Sales (2010E-2014E)
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&D Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity